explore -WSS

explore

author：fashion 2025-08-19 18:02:37 - browse：445

An artist's rendering of the building — currently under construction along Boston's Fort Point Channel — where Eli Lilly plans to open its Institute for Genetic Medicine. Courtesy Alexandria Real Estate Equities Inc

Eli Lilly and Co., which transformed itself from a stodgy underperformer into one of the world’s hottest pharmaceutical companies, said this week that the genetic medicine research center it plans to open in Boston in August will eventually employ twice as many workers as originally estimated.

In February 2022, Lilly said that it would increase its modest Massachusetts workforce from 120 to 250 employees when it opened the $700 million Lilly Institute for Genetic Medicine along Fort Point Channel. The Indianapolis-based company said it would move 120 scientists from Kendall Square in Cambridge to the institute and add another 130.

But Daniel Skovronsky, Lilly’s chief scientific and medical officer, said in an interview that the 12-story, 334,000-square-foot laboratory and office building will ultimately accommodate 500 Lilly scientists and researchers.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

leisure time

focus

WSS

Poor hospice wound care hurts patients and families

CDC advisers recommend seasonal use of Pfizer RSV shot

Poor hospice wound care hurts patients and families

How Vertex's cystic fibrosis drug is changing patients' lives

Biotech stock slump in 2023: awaiting the turnaround

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

leisure time

explore

Wikipedia

Bright Health sells Medicare Advantage business to Molina

In key trial, Verve's treatment lowers cholesterol levels in patients

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Sports medicine is finally prioritizing gender equality

Drug for rare kidney disease narrowly misses mark in clinical trial

DIEP, the 'gold standard' of breast reconstruction, is under threat

Experts study whether long Covid risk adds up with each reinfection

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

focus

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

World's first CRISPR

Hearing on Medicare drug price negotiation gets unusually heated

David Sabatini, ex

How Vertex's cystic fibrosis drug is changing patients' lives

World's first CRISPR

leisure time

leisure time

focus

Wikipedia